Atria Investments Inc Decreases Stake in United Therapeutics Co. (NASDAQ:UTHR)

Atria Investments Inc lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 29.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 849 shares of the biotechnology company’s stock after selling 350 shares during the period. Atria Investments Inc’s holdings in United Therapeutics were worth $304,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. UniSuper Management Pty Ltd increased its holdings in United Therapeutics by 133.3% in the first quarter. UniSuper Management Pty Ltd now owns 700 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 400 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in shares of United Therapeutics by 567.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after acquiring an additional 153,700 shares during the last quarter. Bayesian Capital Management LP acquired a new stake in shares of United Therapeutics during the 1st quarter worth about $772,000. B. Riley Wealth Advisors Inc. purchased a new stake in United Therapeutics during the first quarter worth approximately $219,000. Finally, California State Teachers Retirement System boosted its holdings in United Therapeutics by 2.1% in the first quarter. California State Teachers Retirement System now owns 74,773 shares of the biotechnology company’s stock valued at $17,177,000 after purchasing an additional 1,525 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the sale, the director now directly owns 5,783 shares of the company’s stock, valued at $2,384,215.24. This trade represents a 3.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. This trade represents a 67.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 117,496 shares of company stock valued at $43,765,042 over the last quarter. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Trading Up 1.5 %

United Therapeutics stock opened at $372.89 on Friday. The stock has a market capitalization of $16.65 billion, a price-to-earnings ratio of 16.38, a PEG ratio of 1.05 and a beta of 0.56. The stock has a 50 day moving average of $365.06 and a two-hundred day moving average of $331.37. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the firm posted $5.38 EPS. Equities analysts predict that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Bank of America cut their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. Finally, Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.